NCT06839703View on ClinicalTrials.gov

International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2027

Conditions

High-risk GD2-Positive Ewing Sarcoma

Interventions

DRUG

Dinutuximab beta

Dinutuximab beta is added in different dosages to the standard chemotherapy

All Listed Sponsors

lead

Prof. Dr. Dirk Reinhardt

OTHER